Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA

Kishimoto, Hiroyuki; Maehara, Masayuki

doi:10.1007/s11657-015-0231-6

Cited by 77 publications

(64 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, compliance was higher with monthly than with daily therapies. In line with these findings, Kishimoto and Maehara showed that a monthly regimen has better treatment compliance when compared with weekly and daily regimens 18. These results suggest that compliance and potential convenience are inversely related to the administration frequency of a given treatment.…”

Section: Discussionmentioning

confidence: 61%

Gender- and age-related treatment compliance in patients with osteoporosis in Germany

Hadji

Jacob

Kostev³

2016

PPA

View full text Add to dashboard Cite

AimThe purpose of this study was to analyze treatment compliance in osteoporotic patients treated with osteoporosis medications in Germany.MethodsPatients included in the analysis had been diagnosed with osteoporosis with or without fractures and started anti-osteoporotic therapy (bisphosphonates, denosumab, or strontium ranelate) between 2011 and 2014 in a general (GP) or orthopedic practice (OP) setting in Germany. Data pertaining to 6,221 individuals followed in GP and 4,044 individuals followed in OP were analyzed retrospectively. The last follow-up was in December 2015. The main outcome measure was the compliance within the one-year period after the index prescription date. Compliance was measured indirectly and was based on the mean possession ratio (MPR). A multivariate logistic regression model was used to determine the association between MPR (dependent variable) and age, gender, type of practice, type of osteoporosis treatment, therapy frequency, and history of fracture (covariates).ResultsThe mean age of the study group was 73.3 years, and 13.2% of subjects were men. Regarding type of practice, 60.6% of individuals were followed in GP and 39.4% in OP. Noncompliance was observed in 55.2% of the patients. Patients in the age group ≤60 years were at a higher risk of being noncompliant when compared to those in the age group of 61–70 years. Men and patients who received oral drugs were also more likely to be noncompliant than women and patients who received injectable or intravenous drugs. Finally, therapies that were given every three or six months were associated with a decrease in the risk of noncompliance when compared to weekly therapy, whereas daily and monthly treatments were associated with an increased risk.ConclusionCompliance is insufficient in osteoporotic patients treated with osteoporosis medications.

show abstract

Section: Discussionmentioning

confidence: 61%

Gender- and age-related treatment compliance in patients with osteoporosis in Germany

Hadji

Jacob

Kostev³

2016

PPA

View full text Add to dashboard Cite

show abstract

“…As a result, we found that zoledronic acid might be costeffective compared to alendronate if zoledronic acid was expected to improve the proportion of patients who continued treatment for over a year by 10% compared to alendronate with a few exceptions. Recently, Kishimoto and Maehara reported that the 1 year medication possession ratio (MPR), which was used as an indicator of compliance, was 70.6% for weekly oral bisphosphonates in Japan [43]. If we assumed the proportion of patients who continued therapy for over a year in alendronate arm was equal to 70% based on the previous report, the costeffective threshold for the proportion of treatment persistence for over a year in zoledronic acid arm was estimated to be about 80% or more.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness Analysis of Once-Yearly Injection of Zoledronic Acid For The Treatment of Osteoporosis In Japan

2016

View full text Add to dashboard Cite

Summary Model-based economic evaluation was performed to assess the cost-effectiveness of zoledronic acid. Although zoledronic acid was dominated by alendronate, the incremental quality-adjusted life year (QALY) was quite small in extent. Considering the advantage of once-yearly injection of zoledronic acid in persistence, zoledronic acid might be a cost-effective treatment option compared to once-weekly oral alendronate. Introduction The purpose of this study was to estimate the cost-effectiveness of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Methods A patient-level state-transition model was developed to predict the outcome of patients with osteoporosis who have experienced a previous vertebral fracture. The efficacy of zoledronic acid was derived from a published network metaanalysis. Lifetime cost and QALYs were estimated for patients who had received zoledronic acid, alendronate, or basic treatment alone. The incremental cost-effectiveness ratio (ICER) of zoledronic acid was estimated. Results For patients 70 years of age, zoledronic acid was dominated by alendronate with incremental QALY of −0.004 to −0.000 and incremental cost of 430 USD to 493 USD. Deterministic sensitivity analysis indicated that the relative risk of hip fracture and drug cost strongly affected the costeffectiveness of zoledronic acid compared to alendronate. Scenario analysis considering treatment persistence showed that the ICER of zoledronic acid compared to alendronate was estimated to be 47,435 USD, 27,018 USD, and 10,749 USD per QALY gained for patients with a T-score of −2.0, −2.5, or −3.0, respectively. Conclusion Although zoledronic acid is dominated by alendronate, the incremental QALY is quite small in extent. Considering the advantage of annual zoledronic acid treatment in compliance and persistence, zoledronic acid may be a cost-effective treatment option compared to alendronate.

show abstract

“…Mothers who received monthly vitamin D supplementation in the reviewed studies were administered their dose on-site; mothers who received daily supplementation were largely responsible for their own administration. An unrelated study in Japan found that monthly dosing of bisphosphonates for osteoporosis had higher compliance compared to daily and weekly dosing [18]. Additional studies assessing compliance in relation to maternal self-administered vitamin D supplementation need to be conducted to confirm these results.…”

Section: Discussionmentioning

confidence: 99%

Maternal Supplementation of Vitamin D During Lactation to Support Infant Vitamin D Needs: A Systematic Review

Schossow¹,

Clark²,

Harris³

2018

OJPed

View full text Add to dashboard Cite

Human milk is generally considered to be insufficient in vitamin D. However, research completed in the 1980s showed that the vitamin D content of human milk is directly related to maternal serum vitamin D levels and therefore may potentially be adequate if the mother's vitamin D levels are sufficient. Approximately one-third of the adult population, which includes breastfeeding women, in the United States have vitamin D insufficiency or deficiency. Among infants, 90.4% of breastfed infants are vitamin D deficient compared to 15.4% of formula fed infants. The American Academy of Pediatrics (AAP) has therefore recommended all breastfed infants be directly supplemented with 400 IU per day of vitamin D to decrease the risk of vitamin D insufficiency and rickets. According to the AAP, compliance rates with this recommendation ranges between 2% -36%. Because the recommendation to supplement may undermine breastfeeding, many pediatricians do not inform their patients of the need to supplement. Additionally, some parents are concerned about directly supplementing their infant as risks may include allergic reactions to the ingredients, aspiration pneumonia, accidental overdose, and changes in intestinal flora and pH which may compromise the immune benefits of human milk. A literature review was conducted to examine the effect of maternal supplementation with vitamin D during lactation on human milk vitamin D content and maternal and infant serum vitamin D levels. Although there is no current consensus regarding dosage and timing of maternal vitamin D supplementation, the literature suggests that high-dose vitamin D supplementation of the lactating mother is as effective at maintaining infant vitamin D levels as direct infant supplementation, while also correcting the mother's vitamin D deficiency. How to cite this paper: Schossow, K., Clark, A.M. and Harris, M.A. (2018) Maternal Supplementation of Vitamin D during Lactation to Support Infant Vitamin D Needs: A Systematic Review. Open Journal of Pediatrics, 8, 255-272.

show abstract

Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA

Cited by 77 publications

References 30 publications

Gender- and age-related treatment compliance in patients with osteoporosis in Germany

Gender- and age-related treatment compliance in patients with osteoporosis in Germany

Cost-Effectiveness Analysis of Once-Yearly Injection of Zoledronic Acid For The Treatment of Osteoporosis In Japan

Maternal Supplementation of Vitamin D During Lactation to Support Infant Vitamin D Needs: A Systematic Review

Contact Info

Product

Resources

About